.. .. Liste,

. .. Préambule,

. .. Contexte, 17 Physiopathologie immunitaire et mode d'action des inhibiteurs des points de contrôle immunitaires

. , Les concepts d'immunothérapie ciblée et de « check points

L. and -. .. ,

P. Le-récepteur, ses ligands et les molécules anti PD1

. , Effets indésirables des immunothérapies anti CTLA-4 et anti PD-1

. .. Généralités,

.. .. Effets,

. Matériels and . .. Méthodes,

.. .. Analyse-statistique,

. .. Résultats,

.. .. Caractéristiques,

. , Caractéristiques selon la molécule utilisée et comparaison à la littérature

. .. Conclusion,

. .. Bibliographie,

. .. Résumé,

. Bibliographie,

L. T. Nguyen and P. S. Ohashi, Clinical blockade of PD1 and LAG3-potential mechanisms of action, Nat Rev Immunol, vol.15, issue.1, pp.45-56, 2014.

D. L. Barber, E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison et al., Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.439, issue.7077, pp.682-689, 2006.

E. Buchbinder and F. S. Hodi, Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade, J Clin Invest, vol.125, issue.9, pp.3377-83, 2015.
DOI : 10.1172/jci80012

URL : http://www.jci.org/articles/view/80012/files/pdf

S. Yun, N. D. Vincelette, M. R. Green, W. Hendrickson, A. E. et al., Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaanalysis of anti-CTLA-4 and anti-PD-1 agents trials, Cancer Med, vol.5, issue.7, pp.1481-91, 2016.

R. Chen, P. Peng, B. Wen, F. Li, S. Xie et al., Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis, Transl Oncol, vol.9, issue.1, pp.32-40, 2016.
DOI : 10.1016/j.tranon.2015.11.010

URL : https://doi.org/10.1016/j.tranon.2015.11.010

M. Duruisseaux, I. Rouquette, J. Adam, A. Cortot, A. Cazes et al., Efficacité des inhibiteurs du checkpoint immunitaire PD-1/PD-L1 et testing PD-L1 dans les cancers thoraciques, Ann Pathol, vol.37, issue.1, pp.61-78, 2017.
DOI : 10.1016/j.annpat.2016.12.009

J. D. Wolchok and Y. Saenger, The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation. The Oncologist, vol.13, pp.2-9, 2008.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.2010, issue.363, pp.711-723, 2010.
DOI : 10.1056/nejmoa1003466

Y. Li, F. Li, F. Jiang, X. Lv, R. Zhang et al., A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints, Int J Mol Sci, vol.17, issue.12, p.1151, 2016.

E. D. Deeks, Pembrolizumab: A Review in Advanced Melanoma, Drugs, vol.76, issue.3, pp.375-86, 2016.
DOI : 10.1007/s40265-016-0543-x

T. K. Eigentler, J. C. Hassel, C. Berking, J. Aberle, O. Bachmann et al., Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev, vol.45, pp.7-18, 2016.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immunerelated adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer, vol.54, pp.139-187, 2016.
DOI : 10.1016/j.ejca.2015.11.016

S. Iwama, A. De-remigis, M. K. Callahan, S. F. Slovin, J. D. Wolchok et al., Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody, Sci Transl Med, vol.6, issue.230, pp.230-275, 2014.

P. Iglesias, A. Soria, and J. J. Díez,

, Med Clin (Barc), vol.145, pp.264-272, 2015.

S. M. Corsello, A. Barnabei, P. Marchetti, D. Vecchis, L. Salvatori et al., Endocrine Side Effects Induced by Immune Checkpoint Inhibitors, J Clin Endocrinol Metab, vol.98, issue.4, pp.1361-75, 2013.

F. Torino, S. M. Corsello, and R. Salvatori, Endocrinological side-effects of immune checkpoint inhibitors, Curr Opin Oncol, vol.28, issue.4, pp.278-87, 2016.

J. De-filette, Y. Jansen, M. Schreuer, H. Everaert, B. Velkeniers et al., Incidence of ThyroidRelated Adverse Events in Melanoma Patients Treated With Pembrolizumab, J Clin Endocrinol Metab, vol.101, issue.11, pp.4431-4440, 2016.

M. A. Win, K. Z. Thein, A. Qdaisat, and S. Yeung, Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism, Am J Emerg Med, 2017.

R. Barroso-sousa, W. T. Barry, A. C. Garrido-castro, F. S. Hodi, L. Min et al., Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis, JAMA Oncol, 2017.

, Good pharmacovigilance practices)-Mise à jour prenant en compte l'arrêté du 10 juin 2011 relatif aux modalités de signalement des effets indésirables par les patients et les associations agréées de patients, Bonnes pratiques de pharmacovigilance

, OPDIVO-EPAR summary of product characteristics, 2017.

, KEYTRUDA-EPAR summary of product characteristics, 2017.

, YERVOY-EPAR summary of product characteristics, 2017.

M. Ryder, M. Callahan, M. A. Postow, J. Wolchok, and J. A. Fagin, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer, vol.21, issue.2, pp.371-81, 2014.

J. C. Osorio, A. Ni, J. E. Chaft, R. Pollina, M. K. Kasler et al., Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol, vol.28, issue.3, pp.583-589, 2017.
DOI : 10.1093/annonc/mdw640

URL : https://academic.oup.com/annonc/article-pdf/28/3/583/24169269/mdw640.pdf

F. Illouz, C. Briet, L. Cloix, L. Corre, Y. Baize et al., Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists, Cancer Med
DOI : 10.1002/cam4.1145

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1145

,

L. Min, A. Vaidya, and C. Becker, Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy, Eur J Endocrinol, vol.164, issue.2, pp.303-310, 2011.
DOI : 10.1530/eje-10-0833

URL : https://eje.bioscientifica.com/downloadpdf/journals/eje/164/2/303.pdf

D. S. Cooper, Subclinical hypothyroidism, N Engl J Med, vol.345, issue.4, pp.260-265, 2001.
DOI : 10.4103/0973-0354.106807